Biocon Ltd. NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

346.45 5.45 (1.60%)

2.0M

NSE+BSE Volume

NSE 01 Oct, 2025 3:31 PM (IST)

Board Meeting

The latest board meeting for Biocon Ltd. took place on 01 Oct 2025, for the purpose of Redemption (Part) of NCD See details

Biocon Ltd. share price target

Biocon Ltd. has an average share price target of 367.20. The consensus estimate represents an upside of 5.99% from the last price of 346.45. View 9 reports from 5 analysts offering long-term price targets for Biocon Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	02 Oct 2025	Biocon	Consensus Share Price Target	346.45	380.11	-	9.72	buy	pdf Detailed Estimates
	15 Feb 2023	Biocon	Motilal Oswal Target	346.45	250.00	238.10 (45.51%)	Target met	Neutral	pdf post cache		Broker Report Increased opex/financial leverage drags earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	16 Nov 2022	Biocon	ICICI Securities Limited Reco Target	346.45	362.00	284.40 (21.82%)		Buy	pdf post cache		Broker Report Growth across segments ICICI Securities Limited Biocon Limited’s (Biocon) Q2FY23 performance was ahead of our estimates led by better than expected results in the generics and research services. Generics revenue was up 17.5% YoY to Rs6.2bn while Research services delivered a robust growth of 25.9% YoY to Rs.7.7bn. pdf Copy Link Share on Share on Share on Share on Alert
	15 Nov 2022	Biocon	ICICI Direct Target	346.45	290.00	283.85 (22.05%)	Target met	Hold	pdf post cache		Broker Report Biocon ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	15 Nov 2022	Biocon	Axis Direct Reco Target	346.45	310.00	283.85 (22.05%)		Hold	pdf post cache		Broker Report Result Update:Biocon Axis Direct Management indicated that R&D costs will increase in the upcoming quarters which may pose threat to the current margins of the company. We, therefore, recommend a HOLD rating on the stock with a TP of Rs 310/share. pdf Copy Link Share on Share on Share on Share on Alert
	10 Aug 2022	Biocon	Geojit BNP Paribas Reco Target	346.45	340.00	311.15 (11.35%)		Hold	pdf post cache		Broker Report BIOCON LTD Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2022	Biocon	ICICI Direct Target	346.45	320.00	306.75 (12.94%)		Hold	pdf post cache		Broker Report Biocon ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	30 Apr 2022	Biocon	ICICI Direct	346.45	380.00	368.45 (-5.97%)		Hold	pdf post cache		Broker Report Biocon ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	29 Apr 2022	Biocon	Axis Direct Target	346.45	420.00	368.45 (-5.97%)		Buy	pdf post cache		Broker Report Result Update:Biocon Axis Direct We recommend a BUY rating on the stock with a Target Price of Rs 420. pdf Copy Link Share on Share on Share on Share on Alert
	04 Mar 2022	Biocon	ICICI Securities Limited Target	346.45	390.00	328.20 (5.56%)		Hold	pdf post cache		Broker Report Biocon ICICI Securities Limited Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab Revenue breakup FY21: biosimilars (37%), generics (31%), CRAMS (29%)... pdf Copy Link Share on Share on Share on Share on Alert
	28 Feb 2022	Biocon	Motilal Oswal Target	346.45	385.00	344.85 (0.46%)	Target met	Neutral	pdf post cache		Broker Report Biosimilar deal with Viatris completes the value chain in its Biologics business Motilal Oswal BBL (a subsidiary of BIOS) will acquire Viatris' Biosimilar business to create a vertically integrated company in the Biologics segment. With this acquisition, BBL will acquire the commercial infrastructure in developed/emerging markets, rights for all Biosimilar assets (including the in-licensed portfolio), and the option to acquire rights of bAflibercept. This also fills BBL's gap in regulatory development and supply chain management of Biosimilars in the developed market. The management pegs the estimated revenue/EBITDA of Viatris'... pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners